Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study

Gerdes, S. ; Thaçi, D. ; Griffiths, C.E.M. ; Arenberger, P. ; Poetzl, J. ; Wuerth, G. ; Afonso, M. ; Woehling, H.

Journal of the European Academy of Dermatology and Venereology, 2018-03, Vol.32 (3), p.420-427 [Periódico revisado por pares]

England: John Wiley and Sons Inc

Texto completo disponível